子宫内膜癌全腹腔镜与开腹全子宫切除术比较:单中心回顾性队列研究
该单中心回顾性队列纳入2002至2020年1532例子宫内膜癌手术患者,比较全腹腔镜全子宫切除术(TLH)与开腹全子宫切除术(TAH)的手术结局与肿瘤结局;TLH手术时间更短、输血更少、淋巴结切除更多、住院更短,但TAH组5年总生存与无复发生存更优,Ⅰ期 disease 无显著生存差异。
要点
- TLH较TAH手术时间更短、输血更少、淋巴结切除更多、住院更短。
- TAH组5年总生存与无复发生存优于TLH组,但Ⅰ期患者无显著生存差异。
- 回顾性设计且未校正BMI、合并症、辅助治疗等混杂,结论仅作关联解读。
核心结论
- TLH与减少手术创伤和加快术后恢复相关,但TLH与TAH的肿瘤学结局差异需谨慎解读。
- 因回顾性设计、单中心及协变量校正有限,无法进行因果推断,残余混杂不能排除。
- 手术方式应基于患者风险特征、肿瘤特征和合并症个体化选择。
研究设计与样本
- 回顾性单中心队列研究,地点为波兰凯尔采圣十字癌症中心。
- 纳入2002至2020年期间接受手术治疗的1532例子宫内膜癌患者。
- 采用Kaplan-Meier分析评估生存结局,Cox比例风险模型评估无复发生存(RFS)和总生存(OS)关联。
- 多变量Cox模型校正肿瘤分期、分级、组织学亚型、淋巴血管间隙浸润及淋巴结切除相关变量。
- 未能校正BMI、合并症负担、辅助治疗及手术年份等关键混杂因素。
主要发现
- TLH组平均手术时间显著短于TAH组(121.16 ± 48.79 min vs. 159.26 ± 48.46 min;p < 0.001)。
- 两组术中失血量中位数均为200 mL,但分布差异有统计学意义(p = 0.016)。
- TLH组输血需求低于TAH组(0.6% vs. 5.5%;p = 0.003)。
- TLH组淋巴结切除中位数多于TAH组(10枚 vs. 6枚;p < 0.001),住院中位数更短(4天 vs. 7天;p < 0.001)。
- TAH组5年总生存和无复发生存均优于TLH组(p = 0.001和p = 0.010),但Ⅰ期疾病中两种术式无显著生存差异(p > 0.05)。
临床怎么用
- TLH可用于减少手术创伤、输血需求和住院时间,但需结合患者风险特征个体化选择术式。
- 对存在混杂因素(如BMI、合并症、辅助治疗)的患者,不能仅凭本研究推断TLH与TAH的因果优劣。
- Ⅰ期子宫内膜癌患者两种术式生存差异不显著,术式选择可综合考虑肿瘤特征与患者合并症。
局限性
- 回顾性单中心设计,研究时间跨度长,可能存在选择偏倚和时间趋势影响。
- 未能校正BMI、合并症负担、辅助治疗及手术年份等关键混杂因素,存在残余混杂和适应证混杂。
- findings 应解释为关联而非因果效应,因果推断本身受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate and contrast the surgical effectiveness and oncological outcomes of total laparoscopic hysterectomy (TLH) versus total abdominal hysterectomy (TAH) in individuals diagnosed with endometrial cancer. DESIGN: Retrospective evaluation. SETTING: Holy Cross Cancer Centre in Kielce, Poland. POPULATION: 1532 patients who underwent operative management over the period from 2002 to 2020. METHODS: Survival outcomes were assessed using Kaplan-Meier analysis, and Cox proportional hazards models were applied to evaluate associations with recurrence-free survival (RFS) and overall survival (OS). Multivariable Cox models were adjusted for tumour stage, grade, histological subtype, lymphovascular space invasion, and lymphadenectomy-related variables. No adjustment for key confounders, including body mass index (BMI), comorbidity burden, adjuvant therapy, and year of surgery, was possible, which may introduce residual confounding and confounding by indication. Given the retrospective single-centre design and the extended study period, findings should be interpreted as associations rather than causal effects, as causal inference is inherently limited in this context. MAIN OUTCOME MEASURES: Comparative efficacy of TLH versus TAH in terms of surgical outcomes (operative time, blood loss, transfusion requirements, lymph node yield, hospital stay) and oncological outcomes (recurrence-free survival (RFS) and overall survival (OS)). RESULTS: TLH was associated with a significantly shorter mean operative time (121.16 ± 48.79 min vs. 159.26 ± 48.46 min; p < 0.001), lower intraoperative blood loss (median 200 mL in both groups, p = 0.016 indicating differences in distribution), reduced need for blood transfusion (0.6% vs. 5.5%; p = 0.003), more extensive lymphadenectomy (median 10 nodes vs. 6 nodes; p < 0.001) and shorter hospital stay (median 4 days vs. 7 days; p < 0.001). However, five-year overall survival (OS) and recurrence-free survival (RFS) were superior in the TAH group (p = 0.001 and p = 0.010, respectively). No statistically significant survival differences were observed between the two approaches in stage I disease (p > 0.05). These findings may be influenced by unmeasured confounding, selection bias, and temporal changes in clinical practice over the study period. CONCLUSIONS: TLH is associated with reduced surgical trauma and faster postoperative recovery, whereas differences in oncological outcomes between TLH and TAH should be interpreted with caution. No causal inference can be drawn due to the retrospective design, single-centre setting, and limited covariate adjustment, as residual confounding cannot be excluded. Surgical approach should be individualised based on patient risk profile, tumour characteristics and comorbidities.
引用
- Misiek M, Kukla-Jakubowska A, Picheta A, et al. Comparison of Total Laparoscopic Hysterectomy and Total Abdominal Hysterectomy in Endometrial Cancer: A Retrospective Single-Centre Cohort Study. BJOG. 2026. PMID: 42141796. doi:10.1111/1471-0528.70267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。